Laurion Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Laurion Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-280,589	Closed	-$12.6M	–	2025
2017 Q3	$12.6M	Buy	+280,589	New	+$9.57M	0.06%	274
2017 Q2	–	Sell	-17,581	Closed	-$390K	–	2037
2017 Q1	$390K	Buy	+17,581	New	+$377K	﹤0.01%	988
2016 Q2	–	Sell	-8,200	Closed	-$312K	–	1154
2016 Q1	$312K	Buy	+8,200	New	+$286K	﹤0.01%	585
2015 Q2	–	Sell	-67,200	Closed	-$4.08M	–	741
2015 Q1	$4.08M	Buy	67,200 +17,200	+34%	+$835K	0.08%	176
2014 Q4	$2.61M	Buy	+50,000	New	+$2.24M	0.06%	117

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Laurion Capital Management's JUNO Position: Q4 2017 in Review

Laurion Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 280,589 shares — an estimated $12.6M sold.

Laurion Capital Management first reported a position in JUNO in Q4 2014 and held it in 5 quarters. The position peaked at $12.6M in Q3 2017. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

Laurion Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Laurion Capital Management sold 280,589 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $12.6M.
Laurion Capital Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 5 quarters.
Laurion Capital Management's Juno Therapeutics, Inc. position peaked at $12.6M in Q3 2017.
237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Laurion Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.